Suppr超能文献

在妊娠不同阶段的怀孕母猪中接种改良活病毒PRRS 1型疫苗后的安全性和繁殖性能评估。

Assessment of safety and reproductive performance after vaccination with a modified live-virus PRRS genotype 1 vaccine in pregnant sows at various stages of gestation.

作者信息

Stadler Julia, Zoels Susanne, Eddicks Matthias, Kraft Christian, Ritzmann Mathias, Ladinig Andrea

机构信息

Clinic for Swine at the Centre for Clinical Veterinary Medicine, Ludwig-Maximilians University, Oberschleissheim, Germany.

Boehringer Ingelheim Veterinary Research Center GmbH & Co. KG, Hannover, Germany.

出版信息

Vaccine. 2016 Jul 19;34(33):3862-6. doi: 10.1016/j.vaccine.2016.05.042. Epub 2016 Jun 7.

Abstract

The objective of the present study was to assess safety and efficacy of a new modified live-virus porcine reproductive and respiratory syndrome (PRRS) genotype 1 vaccine in pregnant sows at various stages of gestation under field conditions. A total of 505 sows and gilts were allocated to two treatment groups and maintained in separate facilities. Animals of group 1 were vaccinated with a commercial modified live genotype 1 PRRSV vaccine (control product, CP), while animals of group 2 were immunized with a new modified live genotype 1 PRRSV vaccine (investigational veterinary product, IVP) (ReproCyc® PRRS EU, Boehringer Ingelheim Vetmedica GmbH). Injection site reactions were noted to be significantly less frequent in the IVP group compared to the CP group for pain (p=0.039), redness (p=0.030), heat (p=0.016) and swelling (p=0.002). The mean total number of piglets alive at weaning did not differ significantly between both study groups (10.6 vs. 11.0, p=0.375). However, pre-weaning mortality was significantly higher (p=0.005) in piglets from the CP group (14.1% vs. 10.9%). Analyses of reproductive performance data for both groups did not result in statistically significant differences between CP group and IVP group for number of piglets alive (12.7 and 12.6, respectively), healthy live (11.9 and 11.8), weak (0.7 and 0.5), stillborn (1.0 and 0.8) and mummified piglets (0.3 and 0.2) per litter. No differences were detected between both groups for piglet birth weights, while body weights at weaning (7.2kg vs. 6.6kg, p=0.026) and average daily gain (0.2445kg vs. 0.2211kg, p=0.037) were significantly higher in piglets from the IVP group. In conclusion, the administration of a single dose of ReproCyc® PRRS EU to sows and gilts at various stages of gestation confirmed non-inferiority to a commercial PRRS vaccine regarding safety and efficacy parameters under field conditions.

摘要

本研究的目的是评估一种新型改良活病毒猪繁殖与呼吸综合征(PRRS)1型疫苗在田间条件下对不同妊娠阶段的怀孕母猪的安全性和有效性。总共505头母猪和后备母猪被分配到两个治疗组,并饲养在不同的设施中。第1组动物接种了一种商业改良活1型PRRSV疫苗(对照产品,CP),而第2组动物则用一种新型改良活1型PRRSV疫苗(研究用兽用产品,IVP)(ReproCyc® PRRS EU,勃林格殷格翰动物保健有限公司)进行免疫。与CP组相比,IVP组的注射部位反应在疼痛(p = 0.039)、发红(p = 0.030)、发热(p = 0.016)和肿胀(p = 0.002)方面的发生频率显著较低。两个研究组断奶时存活仔猪的平均总数没有显著差异(10.6对11.0,p = 0.375)。然而,CP组仔猪的断奶前死亡率显著更高(p = 0.005)(14.1%对10.9%)。两组繁殖性能数据的分析结果显示,CP组和IVP组在每窝存活仔猪数(分别为12.7和12.6)、健康存活仔猪数(11.9和11.8)、弱仔猪数(0.7和0.5)、死产仔猪数(1.0和0.8)和木乃伊化仔猪数(0.3和0.2)方面没有统计学上的显著差异。两组仔猪的出生体重没有差异,而IVP组仔猪的断奶体重(7.2千克对6.6千克,p = 0.026)和平均日增重(0.2445千克对0.2211千克,p = 0.037)显著更高。总之,在田间条件下,对处于不同妊娠阶段的母猪和后备母猪单剂量接种ReproCyc® PRRS EU在安全性和有效性参数方面证实不劣于一种商业PRRS疫苗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验